文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

韩国单中心幼年型粒单核细胞白血病RAS通路突变特征分析

Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
PubMed 文献 · Br J Haematol · 2021-09-30

该单中心研究纳入24例幼年型粒单核细胞白血病(JMML)患儿,分析其基因谱与临床实验室特征。88%患者存在RAS通路突变,25%存在继发突变。NRAS阳性患者5年EFS高于NRAS阴性患者,但差异无统计学意义。

要点

  • JMML患者RAS通路突变率高达88%,以PTPN11和NRAS最为常见。
  • 25%患者可检出继发突变,包括SETBP1、JAK3、ASXL1等基因。
  • NRAS阳性者5年EFS数值上优于NRAS阴性及PTPN11阳性者,但差异未达统计学显著。

核心结论

  • 韩国JMML患者RAS通路突变发生率为88%,继发突变为25%,NRAS阳性者5年EFS数值上高于NRAS阴性及PTPN11阳性者但差异无统计学意义。

研究设计与样本

  • 单中心回顾性研究,共纳入24例在单一机构诊断并治疗的JMML患者,分析其遗传谱与临床及实验室特征的关联。

主要发现

  • RAS通路突变见于88%患者:PTPN11 9例(38%)、NRAS 9例(38%)、KRAS 2例(8%)、NF1 5例(21%)、CBL 1例(4%)。
  • 继发突变见于25%患者,包括SETBP1、JAK3、ASXL1、GATA2、KIT、KDM6A和BCOR。
  • 6例患者存在细胞遗传学异常,其中3例为单体7。

关键数值与推荐

  • RAS通路突变:PTPN11 38%、NRAS 38%、KRAS 8%、NF1 21%、CBL 4%。
  • 继发突变率25%;细胞遗传学异常6例,其中单体7共3例。

临床怎么用

  • 对JMML患儿应常规进行RAS通路及继发突变基因检测以明确分子分型。
  • NRAS突变状态和PTPN11突变状态可为预后分层提供参考信息。
  • 多数患者接受清髓性预处理后异基因造血干细胞移植,供者多为单倍体家庭成员。

局限性

  • 单中心小样本研究(24例),统计效能有限。
  • 原文未报告多因素校正分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Juvenile myelomonocytic leukaemia (JMML), a rare clonal haematopoietic disorder of childhood, is characterised as a myelodysplastic/myeloproliferative neoplasm. Despite ground-breaking genetic discoveries, JMML remains difficult to diagnose given its diverse clinical features and disease course. A total of 24 patients with JMML were diagnosed and treated at a single institution, and their genetic profiles and association with clinical and laboratory characteristics were analysed. In all, 22 of the patients received allogeneic haematopoietic stem cell transplantation after myeloablative conditioning, mostly from a haploidentical family donor. RAS pathway mutations were identified in 88% of patients: PTPN11 [nine (38%)], NRAS [nine (38%)], KRAS [two (8%)], NF1 [five (21%)] and CBL [one (4%)]. Secondary mutations were found in 25% of patients: SETBP1, JAK3, ASXL1, GATA2, KIT, KDM6A, and BCOR. Six patients showed cytogenetic abnormalities, including three with monosomy 7. The estimated 5-year event-free survival (EFS) and overall survival (± standard error) of the entire cohort were 58·9 (10·9)% and 73·5 (10·8)% respectively. NRAS (+) patients had a higher 5-year EFS than NRAS (-) patients [72·9 (16·5)% vs. 52·5 (13·1)%, P = 0·127]. NRAS (+) patients had a better 5-year EFS than PTPN11 (+) patients [41·7 (17·3)%, P = 0·071]. Our study revealed the genetic characteristics of Korean JMML patients with RAS pathway and secondary mutations.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kim HS, Lee JW, Kang D, et al. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea. Br J Haematol. 2021. PMID: 34590720. doi:10.1111/bjh.17861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。